Temozolomide has been used for the treatment of melanoma with effects comparable to DTIC, and regimens are currently under development that involve more extensive administration. In this report from Memorial Sloan Kettering, patients treated on a daily schedule for 6 weeks or more before a treatment break were observed to develop significant lymphopenia and a higher-than-expected incidence of opportunistic infections.